PPCB (Propanc Biopharma) Total Equity: $10.83 Mil (As of Mar. 2026)


PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.48
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma Total Equity?

Propanc Biopharma PPCB +1.36% 29 Total Equity is $10.83 Mil as of Mar. 2026. GuruFocus rates PPCB with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Propanc Biopharma's total equity for the quarter that ended in Mar. 2026 was $10.83 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Propanc Biopharma Total Equity Historical Data

* Premium members only.

The historical data trend for Propanc Biopharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma Total Equity Chart

Propanc Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.07 -3.02 -3.12 -3.78 13.91

Propanc Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.09 13.91 14.36 11.45 10.83
PPCB
29GF Score
Propanc Biopharma Inc PPCB
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Propanc Biopharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Propanc Biopharma's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=19.632-5.726
=13.91

Propanc Biopharma's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=14.334-3.506
=10.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $10.83 Mil mean?
Propanc Biopharma (PPCB) has a Total Equity of $10.83 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Propanc Biopharma and its competitors.
Is Propanc Biopharma's Total Equity too high?
Propanc Biopharma's current Total Equity is $10.83 Mil. Overall, Propanc Biopharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Propanc Biopharma's Total Equity compare to ENSC and ACUT?
Propanc Biopharma's Total Equity of $10.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Propanc Biopharma and its competitors. Propanc Biopharma's current Total Equity is $10.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Propanc Biopharma stock overvalued right now?
Propanc Biopharma (PPCB) has a current Total Equity of $10.83 Mil. The current Total Equity is $10.83 Mil. Propanc Biopharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Propanc Biopharma (PPCB), the current Total Equity is $10.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.48
Price